Loading clinical trials...
Loading clinical trials...
Transarterial Chemoembolization Combined With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase II, Single-Arm Clinical Trial
Conditions
Interventions
Transarterial chemoembolization (TACE)
bevacizumab and atezolizumab
Start Date
January 1, 2026
Primary Completion Date
December 31, 2028
Completion Date
December 31, 2029
Last Updated
December 15, 2025
NCT07485114
NCT06066138
NCT06811116
NCT06345508
NCT04380545
NCT07291076
Lead Sponsor
Third Affiliated Hospital, Sun Yat-Sen University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions